Autolus Therapeutics PLC (AUTL)
4.11
+0.11
(+2.75%)
USD |
NASDAQ |
May 02, 16:00
4.115
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Enterprise Value: 853.39M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 853.39M |
| May 01, 2024 | 824.14M |
| April 30, 2024 | 739.04M |
| April 29, 2024 | 770.95M |
| April 26, 2024 | 824.14M |
| April 25, 2024 | 845.41M |
| April 24, 2024 | 879.98M |
| April 23, 2024 | 951.78M |
| April 22, 2024 | 973.06M |
| April 19, 2024 | 962.42M |
| April 18, 2024 | 1.037B |
| April 17, 2024 | 1.048B |
| April 16, 2024 | 1.053B |
| April 15, 2024 | 1.063B |
| April 12, 2024 | 1.095B |
| April 11, 2024 | 1.178B |
| April 10, 2024 | 1.130B |
| April 09, 2024 | 1.204B |
| April 08, 2024 | 1.204B |
| April 05, 2024 | 1.250B |
| April 04, 2024 | 1.226B |
| April 03, 2024 | 1.220B |
| April 02, 2024 | 1.226B |
| April 01, 2024 | 1.271B |
| March 28, 2024 | 1.457B |
| Date | Value |
|---|---|
| March 27, 2024 | 1.420B |
| March 26, 2024 | 1.401B |
| March 25, 2024 | 1.444B |
| March 22, 2024 | 1.441B |
| March 21, 2024 | 1.422B |
| March 20, 2024 | 1.502B |
| March 19, 2024 | 1.202B |
| March 18, 2024 | 1.203B |
| March 15, 2024 | 1.113B |
| March 14, 2024 | 1.085B |
| March 13, 2024 | 1.034B |
| March 12, 2024 | 1.013B |
| March 11, 2024 | 1.018B |
| March 08, 2024 | 1.088B |
| March 07, 2024 | 1.013B |
| March 06, 2024 | 1.076B |
| March 05, 2024 | 1.085B |
| March 04, 2024 | 1.106B |
| March 01, 2024 | 1.209B |
| February 29, 2024 | 1.155B |
| February 28, 2024 | 1.139B |
| February 27, 2024 | 1.188B |
| February 26, 2024 | 1.232B |
| February 23, 2024 | 1.181B |
| February 22, 2024 | 1.171B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-83.08M
Minimum
Jun 15 2022
1.502B
Maximum
Mar 20 2024
296.89M
Average
250.90M
Median
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 146.78M |
| Biodexa Pharmaceuticals Plc | -2.147M |
| NuCana PLC | -13.56M |
| TC BioPharm (Holdings) PLC | 1.496M |
| DBV Technologies SA | -11.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -77.17M |
| Total Expenses (Quarterly) | 40.89M |
| EPS Diluted (Quarterly) | -0.45 |
| Earnings Yield | -29.20% |
| Normalized Earnings Yield | -23.22 |